Bristol Wins First Of Two Important Opdivo/Yervoy First-Line NSCLC Approvals

Data from CheckMate-9LA and -227 that will be presented at the ASCO virtual meeting support a low-dose chemo combo with the two drugs and the newly US FDA-approved chemo-free indication. 

White lung cancer awareness ribbon and lung symbol on red background. November lung cancer awareness month. Healthcare and medicine concept.
ASCO results show durable efficacy in first-line lung cancer • Source: Shutterstock

Having faced defeat with Opdivo (nivolumab) monotherapy, Bristol-Myers Squibb Co. has pinned its hopes for taking back some share of the lung cancer market lost to Merck & Co. Inc.’s Keytruda (pembrolizumab) to combination use of its PD-1 inhibitor with its CTLA-4 inhibitor Yervoy (ipilimumab) based on results from the CheckMate-227 and CheckMate-9LA studies. Now the company stands ready to deliver on that promise, with the US Food and Drug Administration approval on 15 May of Opdivo plus Yervoy in the first-line treatment of metastatic non-small cell lung cancer (NSCLC) with PD-L1 expression of 1% or more and no ALK or EGFR alterations.

Three-year data testing Opdivo plus Yervoy versus chemotherapy in the CheckMate-227 clinical trial – the study that supported the new...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Pipeline Watch: Five Approvals And Twelve Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.

More from Scrip

Executives On The Move: Three New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Trogenix and Quetzal Therapeutics, plus Synendos Therapeutics gains a new CMO from Roche.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.